OncoMatch/Clinical Trials/NCT06220162
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Is NCT06220162 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies chidamide in combination with venetoclax and azacitidine (VAC) for acute myeloid leukemia.
Treatment: chidamide in combination with venetoclax and azacitidine (VAC) — Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: ABL1 fusion
Excluded: BCR fusion
Allowed: FLT3 mutation
Performance status
ECOG 2–3(Limited self-care)
Prior therapy
Must have received: VA regimen
Patients with AML who failed to respond to VA regimen
Cannot have received: radiotherapy
Not received radiotherapy...within 4 weeks prior to enrolment
Cannot have received: treatment regimens other than the VA regimen
Not received...treatment regimens other than the VA regimen...within 4 weeks prior to enrolment
Cannot have received: haematopoietic stem cell transplantation
Not received...haematopoietic stem cell transplantation within 4 weeks prior to enrolment
Cannot have received: chidamide (chidamide)
With prior treatment with chidamide
Lab requirements
Kidney function
creatinine clearance ≥ 30 ml/min to < 45 ml/min
Liver function
moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 x upper limit of normal (uln)
Cardiac function
presence of a cardiac history of congestive heart failure, or ejection fraction ≤ 50%, or presence of chronic stable angina
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify